JusticeItaly Official institution
Italy Revokes Marketing Authorization for Dimetilfumarato Sandoz
Italy's medicines agency, AIFA, has revoked the marketing permission for the human medicine Dimetilfumarato Sandoz. The revocation followed a request from the company holding the permission, which gave it up. The official notice appeared in Italy's Gazzetta Ufficiale (Official Gazette) on 29 October 2026.
What does it mean?
Italy's medicines regulator has cancelled its permission to sell the medicine Dimetilfumarato Sandoz. The cancellation happened because the company that held the permission asked to give it up.
Who is affected?
Patients who use Dimetilfumarato Sandoz in Italy, and the pharmacies and distributors that supply it.
What changes?
Before, the medicine Dimetilfumarato Sandoz was authorized for sale in Italy; now that authorization has been revoked.